Latest news with #Goadsby
Yahoo
04-08-2025
- Business
- Yahoo
Beloved Grade II restaurant in former church up for sale
A beloved Grade II-listed restaurant inside an old church in Lymington is up for sale. The popular Lanes of Lymington, a family restaurant that also offers cooking lessons, is a two-storey restaurant and bar up for more than half a million pounds. Being advertised as a "genuine retirement sale" by estate agents Goadsby, the eatery has hit the market for £525,000. READ MORE: Plan to build new motorway services area beside M27 - this is where The property can cater for 55 people in a historic building which also used to be home to a school. The popular Lanes of Lymington is up for sale. (Image: Zoopla / Goadsby) With the freehold being listed for sale, the building comes with an equipped first floor kitchen and second floor store room and office. Located in a cul-de-sac just off the main High Street, the property sits in what Goadsby calls a desirable area of the attractive Georgian Market Town in Lymington, which is a major yachting centre. The restaurant stands 0.3 miles away from Lymington Town train station.
Yahoo
21-06-2025
- Business
- Yahoo
Laser studio takes business centre to full capacity
A business centre has reached full occupancy following the letting of a ground floor unit. Goadsby Commercial's Hampshire office completed the deal at Hedge End Business Centre in Hedge End, Southampton, securing full occupancy on behalf of a retained client. The 1,436 sq ft unit has been let on a five-year lease to HA Laser Studio, which plans to open a clinic offering laser treatments. READ MORE: Key facts as cruise operator reveals number of staff employed in Southampton Amy Baker at Goadsby said: "Originally constructed as offices, the versatility of the design of the units at Hedge End Business Centre has also lent itself to be suitable for alternative uses within Class E. "This flexibility alongside the convenient location has seen a strong demand in the units. "Unit 12 was an open plan ground floor unit which will be fitted out to the tenants' needs and we look forward to seeing the new studio, which specialises in laser treatments, open in the near future."
Miami Herald
17-05-2025
- Health
- Miami Herald
Drug said to be effective against early migraine symptoms
May 14 (UPI) -- Migraines don't just cause headaches. These attacks often are accompanied by symptoms like light and sound sensitivity, nausea, neck pain and dizziness. What's more, those non-headache symptoms tend to crop up before a full-fledged migraine headache takes root. But now, researchers say they've discovered an already approved migraine drug that can stop these other symptoms hours before a headache starts. Ubrogepant successfully warded off early migraine symptoms in patients who took the drug one to six hours before a headache, causing a 72% increased likelihood a person wouldn't experience light sensitivity and an 85% increased likelihood they wouldn't have fatigue. Doubled likelihood they wouldn't experience neck pain or sound sensitivity. The drug also helped people think and concentrate better despite their oncoming migraine, researchers reported Monday in Nature Medicine. The results suggest that ubrogepant could "free patients from a disabling part of migraine," study co-author Dr. Peter Goadsby, a neuroscientist at King's College London, told Nature. Ubrogepant gained approval from the U.S. Food and Drug Administration in 2019 after studies showed that it reduced headache pain and other migraine symptoms within two hours of taking the pill, according to The drug works by blocking a protein involved in pain and migraines called calcitonin gene-related peptide, or CGRP. Ubrogepant prevents the CGRP protein from attaching to nerve endings. Symptoms that occur prior to a migraine are called "prodome" symptoms. Migraines occur when a brain region called the hypothalamus goes out of whack, and these prodomal symptoms precede the headache. "Not enough attention has been given to prodrome symptoms," Goadsby said, noting that the new study was mean to "fill this gap." For the study, researchers recruited 438 people who could reliably predict oncoming migraine attacks based on their prodomal symptoms. People were randomly assigned to take either ubrogepant or a placebo just before a migraine attack and keep notes on their symptoms. They then waited for their next migraine and took the opposite treatment, be it the medicine or placebo. Participants didn't know what they were taking either time. Patients taking Ubrogepant reported: • Better ability to concentrate within an hour • Reduced light sensitivity within two hours • Reduced fatigue and neck pain after three hours • Reduced sound sensitivity after four hours However, it is essential that people take the drug before their headache if they want to stop these other symptoms, Goadsby said. "People who know their migraine would benefit more from this medicine," he said, arguing that doctors should train patients to detect early migraine symptoms so they can judge when to take ubrogepant. More information Cleveland Clinic has more on migraines. Copyright © 2025 HealthDay. All rights reserved. Copyright 2025 UPI News Corporation. All Rights Reserved.
Yahoo
14-05-2025
- Health
- Yahoo
Drug said to be effective against early migraine symptoms
May 14 (UPI) -- Migraines don't just cause headaches. These attacks often are accompanied by symptoms like light and sound sensitivity, nausea, neck pain and dizziness. What's more, those non-headache symptoms tend to crop up before a full-fledged migraine headache takes root. But now, researchers say they've discovered an already approved migraine drug that can stop these other symptoms hours before a headache starts. Ubrogepant successfully warded off early migraine symptoms in patients who took the drug one to six hours before a headache, causing a 72% increased likelihood a person wouldn't experience light sensitivity and an 85% increased likelihood they wouldn't have fatigue. Doubled likelihood they wouldn't experience neck pain or sound sensitivity. The drug also helped people think and concentrate better despite their oncoming migraine, researchers reported Monday in Nature Medicine. The results suggest that ubrogepant could "free patients from a disabling part of migraine," study co-author Dr. Peter Goadsby, a neuroscientist at King's College London, told Nature. Ubrogepant gained approval from the U.S. Food and Drug Administration in 2019 after studies showed that it reduced headache pain and other migraine symptoms within two hours of taking the pill, according to The drug works by blocking a protein involved in pain and migraines called calcitonin gene-related peptide, or CGRP. Ubrogepant prevents the CGRP protein from attaching to nerve endings. Symptoms that occur prior to a migraine are called "prodome" symptoms. Migraines occur when a brain region called the hypothalamus goes out of whack, and these prodomal symptoms precede the headache. "Not enough attention has been given to prodrome symptoms," Goadsby said, noting that the new study was mean to "fill this gap." For the study, researchers recruited 438 people who could reliably predict oncoming migraine attacks based on their prodomal symptoms. People were randomly assigned to take either ubrogepant or a placebo just before a migraine attack and keep notes on their symptoms. They then waited for their next migraine and took the opposite treatment, be it the medicine or placebo. Participants didn't know what they were taking either time. Patients taking Ubrogepant reported: • Better ability to concentrate within an hour • Reduced light sensitivity within two hours • Reduced fatigue and neck pain after three hours • Reduced sound sensitivity after four hours However, it is essential that people take the drug before their headache if they want to stop these other symptoms, Goadsby said. "People who know their migraine would benefit more from this medicine," he said, arguing that doctors should train patients to detect early migraine symptoms so they can judge when to take ubrogepant. More information Cleveland Clinic has more on migraines. Copyright © 2025 HealthDay. All rights reserved.
Scientific American
14-05-2025
- Health
- Scientific American
Migraine Drug Ubrogepant Tackles Debilitating Early Symptoms
Scientists have shown that a drug approved to treat migraine headaches can also alleviate debilitating non-headache symptoms, such as fatigue, brain fog and blinding light sensitivity, that occur as the migraine is starting. The drug — called ubrogepant — is already known to stop the onset of a full-blown migraine attack in some people if they take it when the headache begins. But a phase III clinical trial, described in Nature Medicine on 12 May, shows that it can also tackle the 'prodrome' symptoms that arrive hours or even days earlier. The results suggest that ubrogepant could 'free patients from a disabling part of migraine,' says study co-author Peter Goadsby, a neuroscientist at King's College London. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Early intervention The process of a migraine starts long before the head pain, when brain circuits involving the hypothalamus — a region that regulates several vital bodily functions — become dysregulated. In the prodrome, or premonitory phase, people can experience various unpleasant symptoms, including fatigue, neck pain, an aversion to light (photophobia) or sound (phonophobia) and difficulty concentrating. 'Not enough attention has been given to prodrome symptoms,' says Goadsby. The trial aimed to 'fill this gap' by investigating whether ubrogepant has an effect on the initial stages of a migraine. The trial included 438 participants who could reliably identify incoming migraine attacks from their prodromal symptoms. During the 60 days of the trial, they took ubrogepant or a placebo whenever they felt any prodromal symptoms coming on, and reported whether doing this had any effect. The results suggest that for some participants, the drug increased their ability to concentrate one hour after treatment, reduced their photophobia two hours after treatment and reduced their fatigue and neck pain after three hours. But the 'effect sizes were small' and never more than 15 percentage points compared with the placebo, points out Gregory Dussor, a neuroscientist and migraine specialist at the University of Texas at Dallas. For example, 27% of participants who took ubrogepant reported an absence of fatigue, compared with 17% who took the placebo. Dussor suggests this modest improvement is because the class of drugs to which ubrogepant belongs is a 'life-changing therapeutic' for a minority of people — perhaps only one in five, according to some studies. It makes little difference to others, so its effect for that minority 'gets diluted in the data'. 'Nevertheless, this study answers the question of whether ubrogepant works when you dose it early in the migraine, when people feel prodromal symptoms coming on,' he says. Know your migraine Ubrogepant is already known to stop migraine headaches, but Goadsby says the data show that it works substantially better if taken in the prodromal stage rather than once the attack starts. In the trial, it was crucial that participants could predict their preliminary symptoms. 'People who know their migraine would benefit more from this medicine,' he says. The next challenge for the field, he adds, is to train people to understand their migraine symptoms so they can judge when to take ubrogepant. Dussor thinks that once the prodrome has begun, it is probably still too late for ubrogepant to block the migraine entirely. He says research should explore another question: 'Is there some way to alert people much earlier to take the drug, before they feel symptoms coming on?' The study could also provide clues about the cause of prodromal symptoms. Ubrogepant works by blocking receptors that bind to calcitonin gene-related peptide (CGRP), a molecule that sensitizes the nerves in the head and skull during a migraine attack. 'Knowing there's some CGRP component earlier than the headache phase is important to know in our mechanistic understanding of migraine,' says Dussor.
